Related Experiment Video
Updated: Jun 20, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked
M Ellen Kuenzig1,2, Thomas D Walters1,2,3, David R Mack4,5,6
1SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, ON, Canada.
Insights
The first year of care for pediatric inflammatory bowel disease (IBD) incurs significant healthcare costs. Initial treatments, surgery, and mental health visits predict higher expenses for children with IBD.
Area of Science:
- Pediatric Gastroenterology
- Health Economics
- Healthcare Management
Background:
- Pediatric inflammatory bowel disease (IBD) incidence and associated healthcare costs are rising.
- Direct healthcare costs in the first year post-diagnosis are substantial.
- Predictive models for high-cost pediatric IBD cases are needed.
Purpose of the Study:
- To calculate the direct healthcare costs for pediatric IBD patients in their first year post-diagnosis.
- To develop a predictive model for identifying children with high healthcare costs (top 25th percentile).
Main Methods:
- Utilized data from the Canadian Children IBD Network inception cohort linked to health administrative data.
- Estimated direct healthcare and medication costs from 31 to 365 days post-diagnosis.
- Employed logistic regression with stepwise elimination and 5-fold cross-validation for model building.
Main Results:
- Mean first-year cost for 487 children with IBD was CA$15,168.
- Predictors of increased costs included initial anti-TNF therapy, aminosalicylates, systemic steroids, mental health encounters, surgery, ED visits, sex, and age.
- Having a regular primary care provider predicted decreased costs (C-statistic: 0.71).
Conclusions:
- The first-year cost of pediatric IBD care is substantial and predictable.
- Identifying high-cost patients at diagnosis is possible.
- Strategies to reduce costs without compromising care quality are essential.
Background:
The incidence of pediatric-onset inflammatory bowel disease (IBD) and the costs of caring for individuals with IBD are both increasing. We calculated the direct healthcare costs of pediatric IBD in the first year after diagnosis and developed a model to predict children who would have high costs (top 25th percentile).
Methods:
Using data from the Canadian Children IBD Network inception cohort (≤16 years of age, diagnosed between 2013 and 2019) deterministically linked to health administrative data from Ontario, Canada, we estimated direct healthcare and medication costs accrued between 31 and 365 days after diagnosis. Candidate predictors included age at diagnosis, sex, rural/urban residence location, distance to pediatric center, neighborhood income quintile, IBD type, initial therapy, disease activity, diagnostic delay, health services utilization or surgery around diagnosis, regular primary care provider, and receipt of mental health care. Logistic regression with stepwise elimination was used for model building; 5-fold nested cross-validation optimized and improved model accuracy while limiting overfitting.
Results:
The mean cost among 487 children with IBD was CA$15 168 ± 15 305. Initial treatment (anti-tumor necrosis factor therapy, aminosalicylates, or systemic steroids), having a mental health care encounter, undergoing surgery, emergency department visit at diagnosis, sex, and age were predictors of increased costs, while having a regular primary care provider was a predictor of decreased costs. The C-statistic for our model was 0.71.
Conclusions:
The cost of caring for children with IBD in the first year after diagnosis is immense and can be predicted based on characteristics at diagnosis. Efforts that mitigate rising costs without compromising quality of care are needed.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

